Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events

被引：0
|
作者：
Sara Lee
Christopher P. Cannon
机构：
[1] Temple University School of Pharmacy,Cardiovascular Division, Harvard Medical School
[2] Brigham and Women’s Hospital,undefined
来源：
Current Cardiology Reports | 2018年 / 20卷
关键词：
Statin therapy; PCSK9 inhibitors; Cholesterol; Cardiovascular risk;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
    Michaeli, Daniel Tobias
    Michaeli, Julia Caroline
    Albers, Sebastian
    Boch, Tobias
    Michaeli, Thomas
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (05) : 477 - 495
  • [42] Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?
    Alnima, Teba
    Smits, Mark M.
    Hanssen, Nordin M. J.
    CURRENT OPINION IN LIPIDOLOGY, 2024, 35 (06) : 259 - 267
  • [43] Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies
    Khan, Irfan
    Peterson, Eric D.
    Cannon, Christopher P.
    Sedita, Lauren E.
    Edelberg, Jay M.
    Ray, Kausik K.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (15):
  • [44] New and emerging lipid-lowering therapies for reducing cardiovascular risk: beyond statins
    Luo, Fei
    Yu, Liqing
    Xian, Xunde
    Shan, Bo
    Das, Avash
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [45] Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction
    Sakhuja, S.
    Bittner, V. A.
    Brown, T. M.
    Farkouh, M. E.
    Levitan, E. B.
    Rosenson, R.
    Safford, M. M.
    Muntner, P.
    Chen, L.
    Sun, R.
    Noshad, S.
    Dhalwani, N.
    Woodward, M.
    Colantonio, L. D.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2374 - 2374
  • [46] Combination lipid-lowering therapy in diabetes
    Michael H. Davidson
    Current Diabetes Reports, 2003, 3 (3) : 263 - 268
  • [47] REHOSPITALIZATION DUE TO SUBSEQUENT CARDIOVASCULAR EVENTS IN SECONDARY PREVENTION PATIENTS TREATED WITH LIPID LOWERING THERAPIES IN ITALY
    Sciattella, P.
    Maggioni, A. P.
    Belfiore, M.
    Vilela, Sorio F.
    Kahangire, D. A.
    Mennini, F. S.
    VALUE IN HEALTH, 2019, 22 : S557 - S557
  • [48] LIPID-LOWERING DRUGS IN THE PREVENTION OF ATHEROSCLEROSIS
    PATSCH, JR
    INTERNIST, 1989, 30 (05): : 309 - 314
  • [49] Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention
    Mazhar, Faizan
    Hjemdahl, Paul
    Sjolander, Arvid
    Kahan, Thomas
    Jernberg, Tomas
    Carrero, Juan Jesus
    AMERICAN HEART JOURNAL, 2024, 269 : 118 - 130
  • [50] What is new in lipid-lowering therapies in diabetes?
    Cheung, Yee-Ming
    O'Brien, Richard
    Ekinci, Elif I.
    INTERNAL MEDICINE JOURNAL, 2019, 49 (12) : 1472 - 1480
12345